| Objective To explore the application value of serum lipoprotein a [Lp(a)] in high-grade serous ovarian cancer. Methods A total of 75 high-grade serousovarian cancer patients(experimental group) and 70 patients with benign ovarian diseases(control group) were selected in Anhui Cancer Hospital from January 2020 to June 2022. Firstly, we analyzed the levels of total cholesterol, triglyceride,high density lipoprotein,low density lipoprotein and Lp(a) in these patients.Then the association between the Lp(a) level and clinical stage was analyzed in ovarian cancer.Finally, bioinformatics was performed to investigate the correlation between LPA expression and the stage, prognosis. Results No statistical difference was observed for the levels of total cholesterol, triglyceride, high density lipoprotein and low density lipoprotein between the experimental and control groups. The Lp(a) level in the experimental group(379.95±296.10) mg/L was significantly higher than that in the control group(163.59±153.87 mg/L)(P<0.001).Moreover, Lp(a) levels were significantly higher in stage Ⅲ~Ⅳ(399.12 ± 305.69mg/L)ovarian cancer patients than in stage Ⅰ~Ⅱ(214.07 ± 185.68) mg/L patients(P<0.05).Finally, the results of bioinformatics analysis showed that LPA expression was closely related with clinical stage, chemotherapy efficacy and prognosis of ovarian cancer. Conclusions Serum Lp(a)level significantly rises in patients with ovarian cancer. More importantly, LPA expression is correlated with clinical stage, therapeutic efficacy and prognosis of ovarian cancer, suggesting its potential clinical application value for ovarian cancer. |
